Recombinant Human DR5 Protein，His

DR5, or Death Receptor 5, is a crucial member of the tumor necrosis factor receptor (TNFR) superfamily, playing a pivotal role in mediating apoptosis in various cell types. Research into DR5 has gained considerable attention due to its potential implications in cancer therapy, where the activation of this receptor can lead to programmed cell death in tumor cells, thereby inhibiting tumor growth. The use of recombinant DR5 proteins has emerged as a promising strategy for enhancing anti-cancer immune responses, particularly through the development of agonistic antibodies or CAR T-cell therapies targeting DR5. Studies have demonstrated that engaging DR5 can trigger apoptosis in malignancies resistant to conventional therapies, highlighting its importance as a target for drug development. Additionally, the elucidation of DR5's signaling pathways has provided insights into the complex mechanisms of cell death and survival, paving the way for novel therapeutic approaches. Ongoing research aims to optimize DR5-based therapies, enhance their specificity, improve their efficacy, and minimize potential side effects, making DR5 a focal point in the design of innovative cancer treatments that harness the body's immune system to combat tumors effectively. As a result, understanding the structural and functional characteristics of DR5 recombinant proteins is critical for advancing their therapeutic applications in oncology.